Present status of statin therapy

Trends in Cardiovascular Medicine

Volumn 25, Issue 3, 2015, Pages 216-225

  Opie, Lionel H ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; FLUINDOSTATIN; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TELAPREVIR;

ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; COCHRANE LIBRARY; DIABETES MELLITUS; DIABETIC PATIENT; DRUG CONTRAINDICATION; DRUG MEGADOSE; DRUG SAFETY; DYSLIPIDEMIA; EUROPEAN UNION; GLUCOSE BLOOD LEVEL; HUMAN; KINESIOTHERAPY; LIFESTYLE MODIFICATION; LIVER DISEASE; MEDICAL SOCIETY; MORTALITY; MYOPATHY; PREGNANCY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; VASCULAR DISEASE; ADULT; CHILD; DYSLIPIDEMIAS; PROCEDURES;

ADULT; CHILD; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRIMARY PREVENTION; RISK REDUCTION BEHAVIOR;

EID: 84925212641     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2014.10.002     Document Type: Review

References (44)

1. Stone N.J., Robinson J., Lichtenstein A.H., Merz N.B., Blum C.B., Eckel R.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129(25 Suppl. 2):S1-S45. 10.1161/01.
2. Rosenson R.S., Underberg J.A. Systematic review: evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. Cardiovasc Drugs Ther 2013, 27:465-479.
3. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
4. Shepherd J., Blauw G.J., Murphy M.B., Bollen B.M., Cobbe S.M., Ford I., et al. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 23:1623-1630.
5. Fox K.M., Gandhi S.K., Ohsfeldt R.L., Blasetto J.W., Bays H.E. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States. Curr Med Res Opin 2007, 23:2125-2133.
6. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278. Cholesterol Treatment Trialists (CTT) Collaborators.
7. Gotto A., Opie L.H. Lipid-modifying and antiatherosclerotic drugs. Drugs for the heart 2013, 398-435. Elsevier Saunders, Philadelphia. 8th ed. L.H. Opie, B.J. Gersh (Eds.).
8. Taylor F., Huffman M.D., Macedo A.F., Moore T.H., Burke M., Davey Smith G., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013, 1:CD004816. (31;1:CD004816. doi: 10.1002/14651858.CD004816.pub5). 10.1002/14651858.CD004816.pub5.
9. Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. Cholesterol Treatment Trialists (CTT) Collaboration.
10. Lewington S., Whitlock G., Clarke R., Sherliker P., Emberson J., Halsey J., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370:1829-1839.
11. Moon G.J., Kim S.J., Cho Y.H., Ryoo S., Bang O.Y. Antioxidant effects of statins in patients with atherosclerotic cerebrovascular disease. J Clin Neurol 2014, 140-147.
12. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Beider R., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
13. Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
14. Silva M., Matthews M.L., Jarvis C., Nolan N.M., Belliveau P., Malloy M., et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 2007, 29:253-260.
15. Leeper N.J., Ardehali R., deGoma E.M., Heidenreich P.A. Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival. Circulation 2007, 116:613-618.
16. Puri R., Libby P., Nissen S.E., et al. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging 2014, 15:380-388.
17. Stegman B., Puri R., Cho L., Shao M., Ballantyne C.M., Barter P.J., et al. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. DiabetesCare 2014, [pii: DC_141121].
18. Johnson K.M., Dowe D.A. Accuracy of statin assignment using the 2013 AHA/ACC Cholesterol Guideline Versus the 2001 NCEP ATP III Guideline: Correlation with atherosclerotic plaque imaging. J Am Coll Cardiol 2014, 64:910-919.
19. Robinson J.G. Starting primary prevention earlier with statins. Am J Cardiol 2014, [pii: S0002-9149(14)01598-01598].
20. Mihaylova B., Emberson J., Blackwell L., Keech A., Simes J., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590. Cholesterol Treatment Trialists (CTT) Collaborators.
21. Dominguez-Rodriguez A., Abreu-Gonzalez P., Arroyo-Ucar E., Reiter R.J. Decreased level of melatonin in serum predicts left ventricular remodelling after acute myocardial infarction. J Pineal Res 2012, 53:319-323.
22. Nielsen S.F., Nordestgaard B.G., Bojesen S.E. Statin use and reduced cancer-related mortality. Satins and cancer-related mortality. N Engl J Med 2012, 367:1792-1802.
23. Ridker P.M. LDL cholesterol: controversies and future therapeutic directions. Lancet 2014, 384:607-617.
24. Beckman J.A., Paneni F., Cosentino F., Creager M.A. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J 2013, 34:2444-2452.
25. Macedo A.F., Taylor F.C., Casas J.P., Adler A., Prieto-Merino D., Ebrahim S. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med 2014, 12:51.
26. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
27. Opie L.H. Exercise-induced myalgia may limit the cardiovascular benefits of statins. Cardiovasc Drugs Ther 2013, 27:569-572.
28. Jacobson T.A., Wertz D.A., Hoy T., Kuznik A., Grochulski D., Cziraky M. Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated. Mayo Clin Proc 2008, 83:1316-1325.
29. Gaist D., Rodríguez L.A., Huerta C., Hallas J., Sindrup S.H. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001, 12:565-569.
30. Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia 2013, 56:686-695.
31. Rajanna V., Campbell K.B., Leimberger J., Mohanty B.D., Guyton J.R. Elevation of fasting morning glucose relative to hemoglobin A1c in normoglycemic patients treated with niacin and with statins. J Clin Lipidol 2012, 168-173.
32. Navarese E.P., Buffon A., Andreotti F., Kozinski M., Welton N., Fabiszak T., et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013, 111:1123-1130.
33. Tan J.S., Mitchell P., Rochtchina E., Wang J.J. Statin use and the long-term risk of incident cataract: the Blue Mountains Eye Study. Am J Ophthalmol 2007, 143:687-689.
34. Naci H., Brugts J., Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246,955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes 2013, 6:390-399.
35. Stone N.J., Robinson J.G., Lichtenstein A.H., Merz N.B., Blum C.B., Eckel R.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129(25 Suppl. 2):S1-45.
36. Arampatzis C.A., Goedhart D., Serruys P.W., Saia F., Lemos P.A., de Feyter P. Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention-a Lescol Intervention Prevention Study (LIPS) substudy. Am Heart J 2005, 149:329-335.
37. Kavousi M., Leening M.J., Nanchen D., Greenland P., Graham I.M., Steyerberg E.W., et al. European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. J Am Med Assoc 2014, 311:1416-1423.
38. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J Am Med Assoc 1998, 279:1615-1622.
39. Gotto A.M., Moon J. Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia. Expert Rev Cardiovasc Ther 2010, 8:1079-1090.
40. Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological stupimary preventiony. J Clin Epidemiol 1995, 48:1441-1452. West of Scotland Coronary Prevention StudyGroup.
41. Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. J Am Med Assoc 2006, 295:1556-1565.
42. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994, 344:1383-1389. Scandinavian Simvastatin Survival Study group (4S).
43. Opie L.H., Dalby A.J. Cardiovascular prevention: lifestyle and statins-competitors or companions?. S Afr Med J 2014, 104:168-173.
44. Kokkinos P.F., Faselis C., Myers J., Panagiotakos D., Doumas M. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet 2013, 381:394-399.